Ursheet Parikh, partner at Mayfield and investor in Mammoth Biosciences, traces the evolution of life sciences tech companies that led to the trend of startups focused on creating assets for large pharmaceutical companies to buy. He describes how Mammoth, in contrast, built a platform-based company from the start, guided by their mission to impact and save as many lives as possible.